Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Joint Corp. (NASDAQ: JYNT) files a range of reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a national operator, manager and franchisor of chiropractic clinics. These SEC filings cover its Franchise Operations segment, refranchising activity, regional developer arrangements, credit facilities and stock repurchase programs, among other topics relevant to shareholders and analysts.
On this page, you can review The Joint Corp.’s key filings, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss its retail healthcare business model, classification as a lessor of nonfinancial intangible assets, and the performance of its franchised and company-owned or managed clinics. Current reports on Form 8-K provide timely disclosure of material events, such as asset purchase agreements to sell groups of clinics to franchisees, the acquisition or modification of regional developer rights, amendments to its revolving credit agreement, and board authorizations for additional stock repurchase capacity.
Filings also address accounting and reporting matters, including restatements of previously issued financial statements and related internal control considerations, as well as separation agreements with certain officers. Together, these documents outline how The Joint Corp. structures its franchise and management arrangements, manages its balance sheet and capital allocation, and responds to regulatory and governance requirements.
Stock Titan enhances access to these disclosures with real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the significance of complex filings. Users can quickly identify information related to refranchising transactions, development rights, credit facility amendments and other material events affecting JYNT, without reading every line of each report.
The Joint Corp. reported entering into a letter agreement on January 5, 2026 with Bandera Partners LLC and Jefferson Gramm. Under this agreement, the company will include Mr. Gramm in its slate of nominees for election to the board of directors at the 2026 annual meeting of stockholders and will recommend that stockholders vote in favor of his election.
The agreement also contains voting commitments and standstill obligations for Bandera, along with restrictions on transfers of Joint Corp. common stock held by Bandera until the agreement ends. The letter agreement will remain in effect until the earlier of thirty days before the director nomination deadline for the 2027 annual meeting or January 21, 2027.
The Joint Corp insider activity: A Schedule 13D/Section 16 reporting person increased their stake in the company. Charles E. Jobson, identified as a 10% owner of The Joint Corp (ticker JYNT), reported buying common stock.
On January 6, 2026, he purchased 5,240 shares of common stock in an open-market transaction coded "P" at a price of $8.89 per share. After this transaction, he beneficially owned 1,621,671 common shares, held in direct ownership form according to the filing.
Skylands Capital, LLC, a Wisconsin-based investment adviser, filed a Schedule 13G reporting a passive ownership stake in The Joint Corp. common stock. As of 12/31/2025, Skylands beneficially owned 890,045 shares, representing 6.0% of the outstanding common stock. Skylands has sole voting and sole dispositive power over all 890,045 shares and no shared voting or dispositive power. The firm certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of The Joint Corp.
JOINT Corp received an update to a major shareholder’s disclosure as Bandera Partners and its affiliates reported beneficial ownership of 3,937,296 shares of common stock, or about 26.5% of the shares outstanding as of November 3, 2025. All of these shares are held through Bandera Master Fund, with Bandera Partners and individuals Jefferson Gramm and Gregory Bylinsky sharing voting and dispositive power.
On January 5, 2026, Bandera entered into a Letter Agreement with JOINT Corp under which the company agreed to nominate Jefferson Gramm to its board of directors at the 2026 annual meeting and recommend that stockholders vote for his election. In return, Bandera agreed not to increase its ownership above the current 3,937,296 shares, other than any awards granted to Gramm as a director, until a termination date that falls between 30 days before the 2027 nomination deadline and January 21, 2027. The amendment also notes that the reporting persons have not traded JOINT Corp shares in the past 60 days.
The Joint Corp. (JYNT) director and 10% owner Charles E. Jobson reported open-market purchases of the company’s common stock. On 11/21/2025 he bought 10,000 shares at $8.50 per share, on 11/24/2025 he bought 4,680 shares at $8.36, and on 11/25/2025 he bought 2,081 shares at $8.43. After these transactions, he beneficially owned 1,592,027 JYNT shares held directly.
JOINT Corp (JYNT) disclosed an initial ownership report for investor Charles E. Jobson, who is identified as both a director and a 10% owner of the company. As of the reportable event on 11/11/2025, Jobson beneficially owned 1,575,266 shares of JOINT Corp common stock in direct form. The filing is a Form 3, which serves as the first statement of beneficial ownership when someone becomes an insider subject to reporting requirements.
The Joint Corp. reported Q3 2025 results showing modest top-line growth and a return to profitability. Total revenue was $13.38 million, up from $12.65 million a year ago, driven by higher royalty, franchise, advertising, and software fees as the business shifts toward franchising.
Income from continuing operations was $290,370 versus a loss of $414,383 last year, while discontinued operations contributed $564,639 as the company refranchises and exits company-run clinics. Net income was $855,009 compared with a net loss of $3.17 million in Q3 2024. For the nine months, revenue reached $39.73 million and net income was $1.92 million.
Cash and cash equivalents were $29.70 million at September 30, 2025, up from $25.05 million at year-end. The company repurchased $2.29 million of common stock during the quarter. The network ended the period with 884 franchised clinics and 78 company-owned or managed clinics, for 962 total. As of November 3, 2025, 14,866,192 common shares were outstanding.
The Joint Corp. (JYNT) entered a material definitive agreement to sell the assets of, and grant franchise rights to, 45 company-owned or managed clinics in Southern California to Elite Chiro Group for an aggregate purchase price of $4.5 million, subject to adjustments. The price includes $3,154,500 in cash and $1,345,500 in prorated franchise fees across 45 franchise agreements. Elite Chiro Group will pay a $100,000 non-refundable down payment for exclusivity, with the balance due at closing; if unpaid at closing, the balance will convert into a secured promissory note maturing 60 days from signing.
The transaction is expressly conditioned on assigning existing leases for at least 38 of the 45 clinics or executing specified management agreements, along with customary closing conditions. In connection with the deal, The Joint will acquire non-exclusive development rights for 10 clinics, with a $90,000 development fee. Separately, the Board authorized an additional $12.0 million under the stock repurchase program and extended it through November 4, 2027.
JOINT Corp (JYNT) entered a consent and third amendment to its existing credit agreement with JPMorgan Chase Bank, N.A. on September 30, 2025. The amendment expressly consents to the company's refranchising of all company-owned or managed clinics and extends the maturity date of the company's revolving credit facility to August 31, 2027. The amendment includes customary representations, warranties, and conditions precedent. The filing notes the 2025 Amendment is attached as Exhibit 10.1 and that the short description provided is qualified in its entirety by the full amendment text.
TheJoint operates a rapidly expanded clinic network, growing from eight clinics in 2010 to 967 clinics in operation as of December 31, 2024 and again reporting 967 locations (franchised or company-owned/managed) as of June 30, 2025 across 42 states and D.C. The company’s model emphasizes low-cost, appointment-free chiropractic care with membership plans, charging a 7.0% royalty and a 2.0% national marketing fee on franchised clinics and collecting an initial franchise fee of $39,900. In 2023 management began a plan to refranchise or sell most company-owned clinics and in Q3 2024 expanded that plan to market the full portfolio in geographic clusters. Clinical visits average 15–20 minutes for new patients and 5–7 minutes for returning patients. The prospectus contains customary forward-looking statements and references filings incorporated by reference.